

# Publication Demonstrates Improved Prediction of Response to Anti-HER2 Therapy Using MammaTyper®

*MammaTyper® Identified HER2-positive Patients with Greater Accuracy than Immunohistochemistry*

BERLIN, GERMANY, February 24, 2025 /EINPresswire.com/ -- [Cerca Biotech](#)., a Germany-based diagnostics company, announces the publication of a study highlighting the use of [MammaTyper®](#) in the prediction of response to anti-[HER2](#) therapy in breast cancer.



With MammaTyper® we offer a new tool to better determine HER2 status and potentially improve the outcomes of anti-HER2 therapies."

*Richard Hughes, Cerca Biotech's Commercial Director*

MammaTyper®, a molecular diagnostic test from Cerca Biotech, is a RT-qPCR test for quantitative determination of the mRNA expression of four key biomarkers (ER, PR, HER2, and Ki-67) used in the subtyping of breast cancer. Molecular subtyping is essential for accurate treatment decisions and provides an indication of prognosis.

This recent study was published in *Modern Pathology*

which is the official publication of the United States and Canadian Academy of Pathology. The study demonstrated that MammaTyper® identified HER2-positive patients with greater accuracy than Immunohistochemistry improving the prediction of response to anti-HER2 therapy.

The study was conducted at the University of Nottingham and Nottingham University Hospitals NHS Trust, led by Professor Emad Rakha and Dr. Nehal Atallah. "In our study, we aimed to evaluate the accuracy of the MammaTyper® assay in predicting the response of HER2-positive patients to therapy. This is important because HER2-positive breast cancer (BC), which constitutes 13% to 15% of all breast cancer cases, often shows variable response to anti-HER2 therapies," said Dr. Atallah.

Mr. Richard Hughes, Commercial Director of Cerca Biotech, stated, "This study supports our mission to drive innovations in precision medicine in breast cancer . With MammaTyper® we offer a new tool to better determine HER2 status and potentially improve the outcomes of anti-HER2 therapies."

About Cerca Biotech

Cerca Biotech is a diagnostic company based in Germany focused on bringing novel and innovative diagnostic products to the oncology and women's health market. We strive to introduce the best tests to meet the unmet clinical needs at an affordable cost, with clinical accuracy and rapid results as our focus. Utilising a combination of experienced distributors and direct sales Cerca Biotech has a commercial reach from Germany through the Nordics and Eastern Europe to the Middle East, Africa, India and beyond. Our team comprises of highly experienced commercial, technical and clinical experts in the field of IVD, allowing rapid deployment of novel technologies with a 'get it right first time' strategy.

1. Atallah, N., Makhoulf, S., Li, X. M., Zhang, Y., Mongan, N. P., & Rakha, E. (2025). Prediction of response to anti-HER2 therapy using a multigene assay. *Modern Pathology*, Volume 38, Issue 4, 100713, April 2025. <https://doi.org/10.1016/j.modpat.2025.100713>

For more information

Visit the company website at [www.cercabiotech.com](http://www.cercabiotech.com), or contact [info@cercabiotech.com](mailto:info@cercabiotech.com)

Richard Hughes

Cerca Biotech GmbH

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[YouTube](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/787701538>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.